Welcome to a paradigm shift in biopharmaceutical downstream processing
Why a Paradigm Change?
CHRETO's single-use purification technology offers a paradigm shift for the biopharmaceutical industry by
"The need for better single-use and disposable systems in downstream processing is growing…The move toward disposable upstream bioprocessing will push downstream operations toward innovative alternatives that may include membrane adsorbers and prepacked single-use chromatography columns."
"Disposable Chromatography: Options Are Increasing" Genetic Engineering News, Dec. 10, 2013
How does it work?
The characteristics of the DAP molecule include 1) easy elution and no leakage, 2) specific binding to product (to secure selective reaction with target protein(s) and easy dissolving of formed DAP-target complexes and 3) tight binding to solid support (to secure immobilization and final removal of DAP molecules from product stream)
The purification process consists of three steps: catch, clean and collect.
Below, two examples of the application of the technology are shown.
The left-hand figure (above) shows the chromatogram profile, with three major protein peaks representing, from left to right: proteins not bound to DAP, proteins washed away from DAP-target complexes and the elution of the DAP-purified IVIG, respectively. Arrows indicate the fractions that are further analysed by SDS-PAGE (figure on the right). Lanes 6-8 on the SDS-PAGE contain highly purified gamma globulins.
High purity was obtained using a single purification step, as can be seen in lane 7-9 on the SDS-gel (right-hand panel above).
The left-hand figure (above) shows the chromatogram profile, with two major protein peaks representing the fractions containing the flow through after reaction with DAP (Fraction 7 and Lane 7 on the SDS gel, right panel above), and the fraction containing the purified mAb (Fraction 8 and Lane 8 on the SDS gel above). Lane 3 shows purified DAP; Lane 4 shows the feedstock used and Lane 6 show the same sample run without addition of DAP. Lanes 1 and 10 include the MW marker.
CHRETO was funded in 2010, as a spin out of Novozymes, by the inventor Jan Kyhse-Andersen and Torben Jørgensen to develop and commercialize a novel protein purification technology for bio-manufacturing.
CHRETO is based on a set of fundamental values
Creativity, Honesty, Respect and Trustworthiness
The company acquired in 2014 the rights to the original IP related to protein purification technology from Novozymes.
A prototype of the technology has been developed and thoroughly tested by industry experts and a leading pharmaceutical company in Europe during 2014-2016.
Vision and Goals
CHRETO has been supported by funding from an Eurostars project, a collaboration agreement with a major European pharmaceutical and Skeikampen Holding ApS together with National grants.
In September 2016, Biotage AB and Brohuvudet AB invested a total of DKK 20 million (15 + 5, respectively) and Innovationsfonden invested DKK 4.6 million in CHRETO to secure development of the proprietary purification technology.
Shareholders (77 %)
Who we are
Meet the the people working at CHRETO
Board of Directors
Kim Bjørnstrup - Chairman of the board
Kim has a management carrier of more than 25 years in the pharmaceutical industry. He graduated from Copenhagen University in 1984 and was licensed as a Lawyer in 1987.
From 1987 to 1992, he was Internal Legal Counsel to Lundbeck AS and Later Coloplast AS.
From 1992 to 2010 he worked at Octapharma AG in Switzerland, a swiss biotech, initially as Licensing manager and the last 10 years Vice Chairman /CEO. The Company had revenues exceeding one billion EURO and 4000 employees.
In 2010, he re-started Xeltis AG a Swiss biotech with a group of investors, specialising in self-generating heart valves.
From 2013 to 2014, he was the CEO of BPL UK a company with revenues of 300 million EURO and 2000 employees.
From 2015 he worked as CEO at Assistance HR Partners AS, where he I s co-owner, a company specialising in management training recruitment and temporary work.
Lars Bäckman - Member of the board
Lars Bäckman holds the position as VP of Corporate Development with Biotage AB since January 2007 and he is also the General Manager of Biotage subsidiary MIP Technologies. Prior joining Biotage, Lars Bäckman held the position as SVP of Corporate Development at Affibody. He has previous experiences acting as a lawyer at the Swedish law firm Hamilton & Co, specialized in Corporate Finance and Mergers & Acquisitions, and from Venture Management at the Business Development firm Googol. Mr. Bäckman holds a LLM from the Stockholm University and was born in 1961.
Sussi Wetterlin - Member of the board
Sussi is CEO of BASTAonline, a company focused on the substitution of chemicals of concern in the Building and Construction sector.
Sussi has more than 20 years of experience from the chemical industry within the environmental and commercial area. Sussi has extensive managerial experience with proven track record of leading international sales organisations during build-up, growth and turnaround phases. She held a position as European Sales Director in the Wood Industry sector with focus on the emerging markets in Eastern Europe and Russia.
Sussi has a M.Sc in Toxicology from Karolinska Institutet in Stockholm
Mario Augusto Maia - Member of the board
Business Development Novozymes A/S
Frank Nygaard - Member of the board
CMC and Project Director, Symphogen A/S
Click on the names to see CV
Get in touch with us to hear more about DAP technology and its exciting potential for the biopharmaceutical and plasma fractionation industries.
Tel: +45 22 92 80 82
Scan to call directly
Scan to send an Email
CHRETO :: Lejrvej 17 :: DK-3500 Værløse :: Denmark :: tel: +45 22 92 80 82 :: Email: email@example.com